View Future GrowthPoxel 과거 순이익 실적과거 기준 점검 0/6Poxel은 연평균 7.8%의 비율로 수입이 증가해 온 반면, Biotechs 산업은 연평균 17%의 비율로 증가했습니다. 매출은 연평균 27.2%의 비율로 감소했습니다.핵심 정보7.81%순이익 성장률16.12%주당순이익(EPS) 성장률Biotechs 산업 성장률30.80%매출 성장률-27.22%자기자본이익률n/a순이익률-178.45%다음 순이익 업데이트15 Jun 2026최근 과거 실적 업데이트공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026Reported Earnings • Dec 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €2.18m (up 88% from 1H 2024). Net loss: €2.62m (loss narrowed 64% from 1H 2024).Reported Earnings • Oct 17Full year 2024 earnings releasedFull year 2024 results: Revenue: €6.64m (up 235% from FY 2023). Net loss: €18.3m (loss narrowed 48% from FY 2023).공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025Reported Earnings • Dec 11First half 2024 earnings releasedFirst half 2024 results: Revenue: €1.16m (up 22% from 1H 2023). Net loss: €7.26m (loss narrowed 72% from 1H 2023).Reported Earnings • Oct 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €1.98m (up 194% from FY 2022). Net loss: €35.1m (loss widened 12% from FY 2022).모든 업데이트 보기Recent updates공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026Board Change • Dec 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Sophie Lapointe was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Dec 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €2.18m (up 88% from 1H 2024). Net loss: €2.62m (loss narrowed 64% from 1H 2024).공시 • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon FranceReported Earnings • Oct 17Full year 2024 earnings releasedFull year 2024 results: Revenue: €6.64m (up 235% from FY 2023). Net loss: €18.3m (loss narrowed 48% from FY 2023).공시 • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.New Risk • Jul 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€51m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€33.0m market cap, or US$38.5m).공시 • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.공시 • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.New Risk • Mar 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.9m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-€51m). Earnings have declined by 6.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (€9.24m market cap, or US$9.70m). Minor Risk Revenue is less than US$5m (€2.2m revenue, or US$2.3m).공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025Reported Earnings • Dec 11First half 2024 earnings releasedFirst half 2024 results: Revenue: €1.16m (up 22% from 1H 2023). Net loss: €7.26m (loss narrowed 72% from 1H 2023).New Risk • Dec 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.81m (US$8.26m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€49m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€7.81m market cap, or US$8.26m). Minor Risk Revenue is less than US$5m (€2.0m revenue, or US$2.1m).공시 • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.공시 • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon FranceReported Earnings • Oct 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €1.98m (up 194% from FY 2022). Net loss: €35.1m (loss widened 12% from FY 2022).New Risk • Sep 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.1m market cap, or US$32.4m).New Risk • Sep 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.2m market cap, or US$32.4m).New Risk • Aug 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€35.1m market cap, or US$38.7m).공시 • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.New Risk • Jun 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€28.8m market cap, or US$30.9m).New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.6m). Market cap is less than US$100m (€25.0m market cap, or US$26.6m).New Risk • Apr 08New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€25.8m market cap, or US$27.9m).Breakeven Date Change • Oct 18Forecast to breakeven in 2024The 2 analysts covering Poxel expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €26.2m in 2024. Average annual earnings growth of 22% is required to achieve expected profit on schedule.New Risk • Oct 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€16m free cash flow). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Negative equity (-€42m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€29m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.6m). Market cap is less than US$100m (€12.4m market cap, or US$13.1m).Reported Earnings • Sep 28First half 2023 earnings releasedFirst half 2023 results: Net loss: €26.2m (loss widened 96% from 1H 2022). Revenue is forecast to grow 90% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in France.Major Estimate Revision • May 23Consensus revenue estimates decrease by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €5.07m to €2.90m. EPS estimate unchanged from -€2.02 per share at last update. Biotechs industry in France expected to see average net income growth of 6.8% next year. Consensus price target of €9.40 unchanged from last update. Share price fell 15% to €0.66 over the past week.공시 • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon FranceMajor Estimate Revision • Mar 29Consensus revenue estimates decrease by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €6.98m to €6.05m. EPS estimate unchanged from -€1.48 per share at last update. Biotechs industry in France expected to see average net income decline 11% next year. Consensus price target down from €13.93 to €7.60. Share price fell 7.9% to €0.70 over the past week.Major Estimate Revision • Feb 17Consensus revenue estimates fall by 32%The consensus outlook for revenues in fiscal year 2022 has deteriorated. 2022 revenue forecast decreased from €7.98m to €5.40m. Forecast losses increased from -€1.02 to -€1.24 per share. Biotechs industry in France expected to see average net income decline 23% next year. Consensus price target of €13.93 unchanged from last update. Share price fell 2.5% to €0.86 over the past week.공시 • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Nov 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €8.20m to €10.4m. EPS estimate unchanged from -€1.02 at last update. Biotechs industry in France expected to see average net income growth of 2.6% next year. Consensus price target of €12.13 unchanged from last update. Share price fell 5.0% to €1.45 over the past week.Reported Earnings • Sep 23First half 2022 earnings releasedFirst half 2022 results: Net loss: €13.4m (loss widened 67% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Biotechs industry in France.Price Target Changed • Aug 15Price target decreased to €11.50Down from €13.43, the current price target is an average from 3 analysts. New target price is 368% above last closing price of €2.46. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €1.13 next year compared to a net loss per share of €0.83 last year.Major Estimate Revision • Jun 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €10.3m to €8.20m. EPS estimate increased from -€1.30 to -€1.16 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target down from €13.43 to €11.75. Share price was steady at €1.58 over the past week.Reported Earnings • May 24Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.83 loss per share (up from €1.16 loss in FY 2020). Revenue: €13.4m (up 97% from FY 2020). Net loss: €23.8m (loss narrowed 25% from FY 2020). Products in clinical trials Phase I: 3 Phase II: 2 Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is expected to shrink by 23% compared to a 129% growth forecast for the pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €11.4m to €14.6m. EPS estimate fell from -€1.26 to -€1.30 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target of €13.43 unchanged from last update. Share price was steady at €1.86 over the past week.Price Target Changed • Apr 27Price target decreased to €13.43Down from €15.95, the current price target is an average from 3 analysts. New target price is 551% above last closing price of €2.07. Stock is down 69% over the past year.Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Major Estimate Revision • Mar 29Consensus revenue estimates fall by 28%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €15.8m to €11.4m. Forecast losses increased from -€1.21 to -€1.26 per share. Biotechs industry in France expected to see average net income growth of 20% next year. Consensus price target down from €15.95 to €13.43. Share price fell 20% to €2.20 over the past week.분석 기사 • Mar 27Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%The analysts covering Poxel S.A. ( EPA:POXEL ) delivered a dose of negativity to shareholders today, by making a...Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.Reported Earnings • Sep 25First half 2021 earnings releasedThe company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €13.3m (up 108% from 1H 2020). Net loss: €8.03m (loss narrowed 33% from 1H 2020).Major Estimate Revision • Jun 29Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €26.8m to €23.3m. EPS estimate unchanged from -€1.09 per share at last update. Biotechs industry in France expected to see average net income decline 7.5% next year. Consensus price target up from €15.50 to €15.95. Share price was steady at €7.09 over the past week.분석 기사 • May 07Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Mar 26Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €6.81m (down 74% from FY 2019). Net loss: €31.9m (loss widened 24% from FY 2019).Is New 90 Day High Low • Jan 18New 90-day high: €7.62The company is up 20% from its price of €6.36 on 20 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 38% over the same period.Price Target Changed • Dec 16Price target lowered to €15.83Down from €17.60, the current price target is an average from 3 analysts. The new target price is 143% above the current share price of €6.51. As of last close, the stock is down 17% over the past year.분석 기사 • Dec 16How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...분석 기사 • Nov 17How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?This article will reflect on the compensation paid to Thomas Kuhn who has served as CEO of Poxel S.A. (EPA:POXEL...Is New 90 Day High Low • Nov 13New 90-day high: €7.19The company is up 7.0% from its price of €6.70 on 14 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.Is New 90 Day High Low • Oct 27New 90-day low: €6.00The company is down 8.0% from its price of €6.50 on 29 July 2020. The French market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.매출 및 비용 세부 내역Poxel가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이ENXTPA:POXEL 매출, 비용 및 순이익 (EUR Millions)날짜매출순이익일반관리비연구개발비30 Jun 258-145131 Mar 257-166131 Dec 247-186130 Sep 244-177130 Jun 242-167231 Mar 242-2681131 Dec 232-3582030 Sep 232-4092230 Jun 232-4492431 Mar 231-3891831 Dec 221-3191230 Sep 220-3091530 Jun 220-2991831 Mar 227-26102231 Dec 2113-24112530 Sep 2114-26102730 Jun 2114-2892931 Mar 2110-30102831 Dec 207-32102730 Sep 2010-30112830 Jun 2014-28122931 Mar 2020-27123431 Dec 1927-26114030 Sep 1935-21104630 Jun 1944-1695131 Mar 1953-785331 Dec 1862185530 Sep 1853-274830 Jun 1843-574231 Mar 1824-1463231 Dec 175-2262130 Sep 173-2261830 Jun 170-2251631 Mar 170-2361631 Dec 160-2461830 Sep 160-2261530 Jun 160-1961331 Mar 160-1651031 Dec 150-124730 Sep 150-104630 Jun 150-935양질의 수익: POXEL 은(는) 현재 수익성이 없습니다.이익 마진 증가: POXEL는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: POXEL는 수익성이 없지만 지난 5년 동안 연평균 7.8%의 속도로 손실을 줄였습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 POXEL의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: POXEL은 수익성이 없어 지난 해 수익 성장률을 Biotechs 업계(7.2%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: POXEL의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 07:51종가2026/06/10 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Poxel S.A.는 8명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Jason ButlerCitizens JMP Securities, LLCDavid SeynnaeveDegroof PetercamPeter WelfordJefferies LLC5명의 분석가 더 보기
공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026
Reported Earnings • Dec 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €2.18m (up 88% from 1H 2024). Net loss: €2.62m (loss narrowed 64% from 1H 2024).
Reported Earnings • Oct 17Full year 2024 earnings releasedFull year 2024 results: Revenue: €6.64m (up 235% from FY 2023). Net loss: €18.3m (loss narrowed 48% from FY 2023).
공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025
Reported Earnings • Dec 11First half 2024 earnings releasedFirst half 2024 results: Revenue: €1.16m (up 22% from 1H 2023). Net loss: €7.26m (loss narrowed 72% from 1H 2023).
Reported Earnings • Oct 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €1.98m (up 194% from FY 2022). Net loss: €35.1m (loss widened 12% from FY 2022).
공시 • Apr 30Poxel S.A. to Report Fiscal Year 2025 Results on Jun 15, 2026Poxel S.A. announced that they will report fiscal year 2025 results at 5:40 PM, Central European Standard Time on Jun 15, 2026
Board Change • Dec 19Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Chairman of the Board Sophie Lapointe was the last independent director to join the board, commencing their role in 2025. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Dec 12First half 2025 earnings releasedFirst half 2025 results: Revenue: €2.18m (up 88% from 1H 2024). Net loss: €2.62m (loss narrowed 64% from 1H 2024).
공시 • Nov 27Poxel S.A., Annual General Meeting, Dec 11, 2025Poxel S.A., Annual General Meeting, Dec 11, 2025. Location: 12 cours de verdun rambaud esplanade de la gare, lyon France
Reported Earnings • Oct 17Full year 2024 earnings releasedFull year 2024 results: Revenue: €6.64m (up 235% from FY 2023). Net loss: €18.3m (loss narrowed 48% from FY 2023).
공시 • Aug 01+ 1 more updatePoxel S.A. Announces Board ChangesPoxel SA announced significant changes within its Board of Directors following the filing for reorganization proceedings. All the current directors of the Company, Ms. Pascale Boissel, Mr. Richard Kender, Mr. Thomas Kuhn, and Mr. Khoso Baluch, submitted their resignations with immediate effect as of July 31, 2025. The Board of Directors decided to replace them individually by co-optation with immediate effect by the following new directors: Ms. Sophie Jacq Lapointe, Mr. Nicolas Trouche, Mr. Amit Kohli, and Mr. Alexandre Bragadir. These co-optations will be subject to ratification at the next general meeting of shareholders of the Company. Ms. Sophie Jacq Lapointe has been appointed by the new Board of Directors as Chairman of the Board of Directors, succeeding Mr. Khoso Baluch. Sophie Jacq Lapointe has over 20 years of experience in the pharmaceutical industry, having held numerous executive roles and contributed to many commercial successes in oncology, immunology, neuroscience, rare diseases, and endocrinology. She has led or been involved in more than twenty product launches in France, across Europe, and in emerging markets, during her time at Roche, Sanofi, and Ipsen. This includes major R&D transformation projects at Sanofi and Ipsen, as well as serving as General Manager for the Belgium–Luxembourg region at Ipsen and the biotech company Perha Pharmaceuticals. For the past two years, she has been advising biotech Chief Executive Officers and executive committees on clinical and commercial development of innovative product portfolios, with successful business development outcomes. Sophie holds a degree from ESSEC Business School. Amit Kohli has over 3 decades of leadership experience operating at the intersection of science, finance, and commercialization. Amit has extensive experience in the diabetes therapy area, having held senior roles at Sanofi (1997-2010) and Becton Dickinson (2011-2016) where he launched diabetes-related products across developed and emerging markets growing them to multi-billion euros in revenue. Lately, as Chief Executive Officer of privately held biotech, Antev (2020 onwards), he led the company’s $75M sale to Medicus. Mr. Kohli has held Global and regional leadership roles at Pharnext, Eurofins, Becton Dickinson, and Sanofi, encompassing sales, marketing, finance, supply chain, and manufacturing. Mr. Kohli earned an M.B.A. in Finance from the Management Development Institute (MDI) Gurgaon, in India, and a Bachelor of Mechanical Engineering from the University of Pune in India. Alexandre Bragadir has been a Senior Investment Director at IPF Partners, a fund specializing in non-dilutive financing for innovative healthcare companies across Europe. He structures and oversees debt investments, having been involved with a dozen companies in the biotech, biopharma, medtech, and digital health sectors over the past six years. He began his career in 2003 in audit at Salustro Reydel before joining BNP Paribas, in strategic client coverage in Portugal, in structured finance in Paris, and in the commodity trade finance team in Geneva. Alexandre holds a degree from ESCP Europe.
New Risk • Jul 11New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (21% average weekly change). Negative equity (-€51m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€2.2m revenue, or US$2.6m). Market cap is less than US$100m (€33.0m market cap, or US$38.5m).
공시 • May 28Poxel SA Announces New Clinical and Scientific Data on TWYMEEG® to Be Presented at the 68th Annual Meeting of the Japan Diabetes SocietyPOXEL SA announced that new clinical and scientific data on TWYMEEG will be presented at the 68th Annual Meeting of the Japan Diabetes Society (JDS 2025), taking place from May 29 to 31, 2025, in Okayama, Japan. A total of 15 presentations, including results from 7 clinical trials, 3 post-hoc analyses and 5 non-clinical studies supported by Sumitomo Pharma, will be delivered by leading Japanese diabetes experts. These findings further confirm TWYMEEG's efficacy in monotherapy and combination therapies, safety, dual mechanism of action and potential benefits in specific patient populations. Main topics include: TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) study (Phase 4 study): confirmation of TWYMEEG®? efficacy and safety in diabetic patients with renal impairment; FAMILIAR Study: confirmation of TWYMEE G®? efficacy and safety in combination with DPP-4 inhibitors; PARADIME Clamp: confirmation of TWYMeeG®? dual mechanism of action in diabetic patients - clinical data showing effects on insulin sensitivity (clamp part) and glucose stimulated insulin secretion (OGTT part); PARADIME TIR: confirmation of TWYMCEG®? effects on glucose variability; PET/MRI Study: confirmation of TWY MEEG®? effect on glucose excretion in the gut.
공시 • Apr 08Poxel SA Announces Regulatory Approval by Japanese Authorities to Expand TWYMEEG®? Package Insert to Include Type 2 Diabetes Patients with Renal ImpairmentPOXEL SA announced that the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan has approved the revision of TWYMEEG®? package insert for patients with renal impairment with eGFR (estimated glomerular filtration rate) less than 45 mL/min/1.73m2. This approval follows positive topline results from the post-marketing clinical study TWINKLE (TWYMEEG®? in diabetic patients with renal impairment: A post-marketing long-term study) in Japanese type 2 diabetic patients with renal impairment, which confirmed TWYMEEG®®?'s safety and tolerability profile, as announced last August1. Based on these results, discussions with the Japanese regulatory authorities were initiated by Sumitomo Pharma, resulting in the approval that will be officially implemented by Sumitomo Pharma as of April 8, 2025.
New Risk • Mar 03New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €9.24m (US$9.70m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€8.9m free cash flow). Share price has been highly volatile over the past 3 months (26% average weekly change). Negative equity (-€51m). Earnings have declined by 6.4% per year over the past 5 years. Shareholders have been substantially diluted in the past year (38% increase in shares outstanding). Market cap is less than US$10m (€9.24m market cap, or US$9.70m). Minor Risk Revenue is less than US$5m (€2.2m revenue, or US$2.3m).
공시 • Jan 24+ 4 more updatesPoxel S.A. to Report First Half, 2025 Results on Sep 23, 2025Poxel S.A. announced that they will report first half, 2025 results on Sep 23, 2025
Reported Earnings • Dec 11First half 2024 earnings releasedFirst half 2024 results: Revenue: €1.16m (up 22% from 1H 2023). Net loss: €7.26m (loss narrowed 72% from 1H 2023).
New Risk • Dec 09New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: €7.81m (US$8.26m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€49m). Earnings have declined by 20% per year over the past 5 years. Shareholders have been substantially diluted in the past year (51% increase in shares outstanding). Market cap is less than US$10m (€7.81m market cap, or US$8.26m). Minor Risk Revenue is less than US$5m (€2.0m revenue, or US$2.1m).
공시 • Nov 08Poxel S.A. Provides Revenue Guidance for the Full Year 2024Poxel S.A. provided revenue guidance for the full year 2024. The company to see the good sales trajectory for TWYMEEG in Japan, which should lead to the achievement of JPY 5 billion net sales in the coming months, at which point, Poxel will be entitled to 10% royalties on all TWYMEEG net sales and a sales-based payment of JPY 500 million (EUR 3.1 million).These amounts, based on recent royalty monetization agreement, will serve to start repayment of bonds to OrbiMed. Additionally, Poxel will benefit from the residual amount of the reserve deposit made under the terms of the agreement with OrbiMed, in addition to the USD 42.5 million proceeds received upon closing.
공시 • Oct 24Poxel S.A., Annual General Meeting, Nov 28, 2024Poxel S.A., Annual General Meeting, Nov 28, 2024. Location: hotel mercure lyon, centre chateau perrache, 12 cours de verdun rambaud esplanade de la gare, lyon France
Reported Earnings • Oct 04Full year 2023 earnings releasedFull year 2023 results: Revenue: €1.98m (up 194% from FY 2022). Net loss: €35.1m (loss widened 12% from FY 2022).
New Risk • Sep 30New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Share price has been highly volatile over the past 3 months (10% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.1m market cap, or US$32.4m).
New Risk • Sep 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€29.2m market cap, or US$32.4m).
New Risk • Aug 19New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 52% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Shareholders have been substantially diluted in the past year (52% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€35.1m market cap, or US$38.7m).
공시 • Aug 07Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in JapanSumitomo Pharma Co., Ltd. and POXEL SA announced topline results obtained from a post-marketing clinical study, TWINKLE (TWYMEEG in diabetic patients with renal impairment: A post-marketing long-term study) (“the Study”), in Japanese type 2 diabetic patients with renal impairment for TWYMEEG Tablets 500 mg (generic name: imeglimin hydrochloride, “the Drug”) being sold in Japan, based on the Risk Management Plan. The Study was an open-label, uncontrolled, long-term study in 60 Japanese type 2 diabetic patients with renal impairment, who had no experience of type 2 diabetes treatment other than diet and exercise therapy or insufficient glycemic management in monotherapy with a hypoglycemic agent excluding insulin formulation. The Drugwas administered at 500 mg twice-daily to patients with moderate and severe renal impairment, characterized by an estimated glomerular filtration rate (eGFR) between 15 mL/min/1.73 m2 or higher to less than 45 mL/min/1.73 m2, or at 500 mg once-daily to patients with end-stage renal disease, characterized by an eGFR less than 15 mL/min/1.73m2, in monotherapy or in combination therapy with a hypoglycemic agent excluding insulin formulation, to evaluate safety and tolerability when administered orally for 52 weeks. The Drug was observed to be safe and well tolerated in Japanese type 2 diabetic patients with renal impairment and no significant differences were found in the incidence of adverse events, their types and severities in this study from previous clinical studies. Specifically, most of the adverse events were mild or moderate in severity. The incidence of serious adverse events was 16.7% (10 of 60 subjects) and causality with the Drug could be ruled out in all cases. Incidence of adverse events leading to study treatment discontinuation was also limited (4 of 60 subjects). At present, administration of the Drug is not recommended for patients with renal impairment with eGFR less than 45 mL/min/1.73m2. Based on the results of the Study, Sumitomo Pharma is planning to conduct discussions with the regulatory authorities in Japan, on revising the package insert in fiscal 20241 for patients with renal impairment with eGFR less than 45 mL/min/1.73m2.
New Risk • Jun 12New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 50% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Shareholders have been substantially diluted in the past year (50% increase in shares outstanding). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€28.8m market cap, or US$30.9m).
New Risk • Apr 17New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.6m). Market cap is less than US$100m (€25.0m market cap, or US$26.6m).
New Risk • Apr 08New major risk - Revenue and earnings growthEarnings have declined by 27% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Negative equity (-€42m). Earnings have declined by 27% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (34% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.7m). Market cap is less than US$100m (€25.8m market cap, or US$27.9m).
Breakeven Date Change • Oct 18Forecast to breakeven in 2024The 2 analysts covering Poxel expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 18% to 2023. The company is expected to make a profit of €26.2m in 2024. Average annual earnings growth of 22% is required to achieve expected profit on schedule.
New Risk • Oct 16New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-€16m free cash flow). Share price has been highly volatile over the past 3 months (9.1% average weekly change). Negative equity (-€42m). Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (€29m net loss in 2 years). Shareholders have been diluted in the past year (21% increase in shares outstanding). Revenue is less than US$5m (€1.5m revenue, or US$1.6m). Market cap is less than US$100m (€12.4m market cap, or US$13.1m).
Reported Earnings • Sep 28First half 2023 earnings releasedFirst half 2023 results: Net loss: €26.2m (loss widened 96% from 1H 2022). Revenue is forecast to grow 90% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in France.
Major Estimate Revision • May 23Consensus revenue estimates decrease by 43%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €5.07m to €2.90m. EPS estimate unchanged from -€2.02 per share at last update. Biotechs industry in France expected to see average net income growth of 6.8% next year. Consensus price target of €9.40 unchanged from last update. Share price fell 15% to €0.66 over the past week.
공시 • May 16Poxel S.A., Annual General Meeting, Jun 21, 2023Poxel S.A., Annual General Meeting, Jun 21, 2023, at 09:00 Central European Standard Time. Location: Mercure Hotel, Lyon Centre Saxe Lafayette, 29 rue de Bonnel, 69003 LYON, France. Lyon France
Major Estimate Revision • Mar 29Consensus revenue estimates decrease by 13%The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from €6.98m to €6.05m. EPS estimate unchanged from -€1.48 per share at last update. Biotechs industry in France expected to see average net income decline 11% next year. Consensus price target down from €13.93 to €7.60. Share price fell 7.9% to €0.70 over the past week.
Major Estimate Revision • Feb 17Consensus revenue estimates fall by 32%The consensus outlook for revenues in fiscal year 2022 has deteriorated. 2022 revenue forecast decreased from €7.98m to €5.40m. Forecast losses increased from -€1.02 to -€1.24 per share. Biotechs industry in France expected to see average net income decline 23% next year. Consensus price target of €13.93 unchanged from last update. Share price fell 2.5% to €0.86 over the past week.
공시 • Jan 04+ 3 more updatesPoxel S.A. to Report Q3, 2023 Results on Nov 08, 2023Poxel S.A. announced that they will report Q3, 2023 results on Nov 08, 2023
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Nov 10Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €8.20m to €10.4m. EPS estimate unchanged from -€1.02 at last update. Biotechs industry in France expected to see average net income growth of 2.6% next year. Consensus price target of €12.13 unchanged from last update. Share price fell 5.0% to €1.45 over the past week.
Reported Earnings • Sep 23First half 2022 earnings releasedFirst half 2022 results: Net loss: €13.4m (loss widened 67% from 1H 2021). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 30% growth forecast for the Biotechs industry in France.
Price Target Changed • Aug 15Price target decreased to €11.50Down from €13.43, the current price target is an average from 3 analysts. New target price is 368% above last closing price of €2.46. Stock is down 58% over the past year. The company is forecast to post a net loss per share of €1.13 next year compared to a net loss per share of €0.83 last year.
Major Estimate Revision • Jun 28Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from €10.3m to €8.20m. EPS estimate increased from -€1.30 to -€1.16 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target down from €13.43 to €11.75. Share price was steady at €1.58 over the past week.
Reported Earnings • May 24Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behindFull year 2021 results: €0.83 loss per share (up from €1.16 loss in FY 2020). Revenue: €13.4m (up 97% from FY 2020). Net loss: €23.8m (loss narrowed 25% from FY 2020). Products in clinical trials Phase I: 3 Phase II: 2 Post-clinical trial products Approved (during full year): 1 Launched (during full year): 1 Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 100%. Over the next year, revenue is expected to shrink by 23% compared to a 129% growth forecast for the pharmaceuticals industry in France. Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has fallen by 35% per year, which means it is performing significantly worse than earnings.
Major Estimate Revision • May 19Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast increased from €11.4m to €14.6m. EPS estimate fell from -€1.26 to -€1.30 per share. Biotechs industry in France expected to see average net income growth of 10% next year. Consensus price target of €13.43 unchanged from last update. Share price was steady at €1.86 over the past week.
Price Target Changed • Apr 27Price target decreased to €13.43Down from €15.95, the current price target is an average from 3 analysts. New target price is 551% above last closing price of €2.07. Stock is down 69% over the past year.
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Board Change • Apr 01Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Major Estimate Revision • Mar 29Consensus revenue estimates fall by 28%The consensus outlook for revenues in 2022 has deteriorated. 2022 revenue forecast decreased from €15.8m to €11.4m. Forecast losses increased from -€1.21 to -€1.26 per share. Biotechs industry in France expected to see average net income growth of 20% next year. Consensus price target down from €15.95 to €13.43. Share price fell 20% to €2.20 over the past week.
분석 기사 • Mar 27Poxel S.A. (EPA:POXEL) Analysts Just Trimmed Their Revenue Forecasts By 28%The analysts covering Poxel S.A. ( EPA:POXEL ) delivered a dose of negativity to shareholders today, by making a...
Board Change • Mar 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 10 experienced directors. 2 highly experienced directors. Member of Scientific Advisory Board Masato Kasuga was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Insufficient board refreshment.
Reported Earnings • Sep 25First half 2021 earnings releasedThe company reported a solid first half result with reduced losses, improved revenues and improved control over expenses. First half 2021 results: Revenue: €13.3m (up 108% from 1H 2020). Net loss: €8.03m (loss narrowed 33% from 1H 2020).
Major Estimate Revision • Jun 29Consensus forecasts updatedThe consensus outlook for 2021 has been updated. 2021 revenue forecast fell from €26.8m to €23.3m. EPS estimate unchanged from -€1.09 per share at last update. Biotechs industry in France expected to see average net income decline 7.5% next year. Consensus price target up from €15.50 to €15.95. Share price was steady at €7.09 over the past week.
분석 기사 • May 07Is Poxel (EPA:POXEL) Weighed On By Its Debt Load?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Mar 26Full year 2020 earnings releasedThe company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2020 results: Revenue: €6.81m (down 74% from FY 2019). Net loss: €31.9m (loss widened 24% from FY 2019).
Is New 90 Day High Low • Jan 18New 90-day high: €7.62The company is up 20% from its price of €6.36 on 20 October 2020. The French market is up 13% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 38% over the same period.
Price Target Changed • Dec 16Price target lowered to €15.83Down from €17.60, the current price target is an average from 3 analysts. The new target price is 143% above the current share price of €6.51. As of last close, the stock is down 17% over the past year.
분석 기사 • Dec 16How Much Did Poxel's(EPA:POXEL) Shareholders Earn From Share Price Movements Over The Last Five Years?The main aim of stock picking is to find the market-beating stocks. But even the best stock picker will only win with...
분석 기사 • Nov 17How Does Poxel's (EPA:POXEL) CEO Pay Compare With Company Performance?This article will reflect on the compensation paid to Thomas Kuhn who has served as CEO of Poxel S.A. (EPA:POXEL...
Is New 90 Day High Low • Nov 13New 90-day high: €7.19The company is up 7.0% from its price of €6.70 on 14 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.
Is New 90 Day High Low • Oct 27New 90-day low: €6.00The company is down 8.0% from its price of €6.50 on 29 July 2020. The French market is flat over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 9.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is per share.